Athos Capital Limited - Net Worth and Insider Trading
Athos Capital Limited Net Worth
The estimated net worth of Athos Capital Limited is at least $19 Million dollars as of 2024-09-28. Athos Capital Limited is the 2102 Investment manager of Canbridge Pharmaceuticals Inc and owns about 56,021,590 shares of Canbridge Pharmaceuticals Inc (HKSE:01228) stock worth over $19 Million. Details can be seen in Athos Capital Limited's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Athos Capital Limited has not made any transactions after 2023-12-15 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Athos Capital Limited
Athos Capital Limited Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Athos Capital Limited owns 1 companies in total, including Canbridge Pharmaceuticals Inc (HKSE:01228) .
Click here to see the complete history of Athos Capital Limited’s form 4 insider trades.
Insider Ownership Summary of Athos Capital Limited
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| HKSE:01228 | Canbridge Pharmaceuticals Inc | 2023-12-15 | 2102 Investment manager |
Athos Capital Limited Latest Holdings Summary
Athos Capital Limited currently owns a total of 1 stock. Athos Capital Limited owns 56,021,590 shares of Canbridge Pharmaceuticals Inc (HKSE:01228) as of December 15, 2023, with a value of $19 Million.
Latest Holdings of Athos Capital Limited
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| HKSE:01228 | Canbridge Pharmaceuticals Inc | 2023-12-15 | 56,021,590 | 0.34 | 18,767,233 |
Holding Weightings of Athos Capital Limited
Athos Capital Limited Form 4 Trading Tracker
According to the SEC Form 4 filings, Athos Capital Limited has made a total of 1 transactions in Canbridge Pharmaceuticals Inc (HKSE:01228) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Canbridge Pharmaceuticals Inc is the acquisition of 52,665,590 shares on December 15, 2023, which cost Athos Capital Limited around $0.
Insider Trading History of Athos Capital Limited
- 1
Athos Capital Limited Trading Performance
GuruFocus tracks the stock performance after each of Athos Capital Limited's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Athos Capital Limited is -55.41%. GuruFocus also compares Athos Capital Limited's trading performance to market benchmark return within the same time period. The performance of stocks bought by Athos Capital Limited within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Athos Capital Limited's insider trading performs compared to the benchmark.
Performance of Athos Capital Limited
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 33.78 |  | | | | |
| Relative Return to S&P 500(%) | 32.41 | | | | | |
Athos Capital Limited Ownership Network
Athos Capital Limited Owned Company Details
What does Canbridge Pharmaceuticals Inc do?
Who are the key executives at Canbridge Pharmaceuticals Inc?
Athos Capital Limited is the 2102 Investment manager of Canbridge Pharmaceuticals Inc. Other key executives at Canbridge Pharmaceuticals Inc include 2101 Beneficial owner Xue James Qun , 2201 Interest of corporation controlled by you Moskey Matthew Love , and 2201 Interest of corporation controlled by you Schulte-Hillen Friedrich Bela .
Canbridge Pharmaceuticals Inc (HKSE:01228) Insider Trades Summary
Over the past 18 months, Athos Capital Limited made 1 insider transaction in Canbridge Pharmaceuticals Inc (HKSE:01228) with a net purchase of 52,665,590. Other recent insider transactions involving Canbridge Pharmaceuticals Inc (HKSE:01228) include a net sale of 0 shares made by Xue James Qun , a net purchase of 52,665,590 shares made by Schulte-Hillen Friedrich Bela , and a net purchase of 52,665,590 shares made by Moskey Matthew Love .
In summary, during the past 3 months, insiders sold 0 shares of Canbridge Pharmaceuticals Inc (HKSE:01228) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Canbridge Pharmaceuticals Inc (HKSE:01228) were sold and 198,537,986 shares were bought by its insiders, resulting in a net purchase of 198,537,986 shares.
Canbridge Pharmaceuticals Inc (HKSE:01228)'s detailed insider trading history can be found in Insider Trading Tracker table.
Canbridge Pharmaceuticals Inc Insider Transactions
Athos Capital Limited Mailing Address
Above is the net worth, insider trading, and ownership report for Athos Capital Limited. Currently GuruFocus does not have mailing address information for Athos Capital Limited.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
